These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 38945902

  • 1. [Resolvin E1 as a potential lead for the treatment of depression].
    Deyama S, Minami M, Kaneda K.
    Nihon Yakurigaku Zasshi; 2024; 159(4):210-213. PubMed ID: 38945902
    [Abstract] [Full Text] [Related]

  • 2. Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex.
    Deyama S, Aoki S, Sugie R, Fukuda H, Shuto S, Minami M, Kaneda K.
    Neurotherapeutics; 2023 Mar; 20(2):484-501. PubMed ID: 36622634
    [Abstract] [Full Text] [Related]

  • 3. [Elucidation of the Mechanisms Underlying the Rapid Antidepressant Actions of Ketamine and Search for Possible Candidates for Novel Rapid-acting Antidepressants].
    Deyama S.
    Yakugaku Zasshi; 2023 Mar; 143(9):713-720. PubMed ID: 37661437
    [Abstract] [Full Text] [Related]

  • 4. Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23.
    Deyama S, Shimoda K, Suzuki H, Ishikawa Y, Ishimura K, Fukuda H, Hitora-Imamura N, Ide S, Satoh M, Kaneda K, Shuto S, Minami M.
    Psychopharmacology (Berl); 2018 Jan; 235(1):329-336. PubMed ID: 29090333
    [Abstract] [Full Text] [Related]

  • 5. Resolvins as potential candidates for the treatment of major depressive disorder.
    Deyama S, Minami M, Kaneda K.
    J Pharmacol Sci; 2021 Sep; 147(1):33-39. PubMed ID: 34294370
    [Abstract] [Full Text] [Related]

  • 6. [Resolvins as novel targets for rapid-acting antidepressants].
    Deyama S.
    Nihon Yakurigaku Zasshi; 2020 Sep; 155(6):381-385. PubMed ID: 33132254
    [Abstract] [Full Text] [Related]

  • 7. Resolution of depression: antidepressant actions of resolvins.
    Deyama S, Kaneda K, Minami M.
    Neurosci Res; 2022 Oct 19. PubMed ID: 36272561
    [Abstract] [Full Text] [Related]

  • 8. The antidepressant-like effect of resolvin E1 in repeated prednisolone-induced depression model mice.
    Aoki S, Deyama S, Sugie R, Ishimura K, Fukuda H, Shuto S, Minami M, Kaneda K.
    Behav Brain Res; 2022 Feb 10; 418():113676. PubMed ID: 34801580
    [Abstract] [Full Text] [Related]

  • 9. IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.
    Deyama S, Kondo M, Shimada S, Kaneda K.
    Transl Psychiatry; 2022 May 17; 12(1):178. PubMed ID: 35577782
    [Abstract] [Full Text] [Related]

  • 10. Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.
    Deyama S, Duman RS.
    Pharmacol Biochem Behav; 2020 Jan 17; 188():172837. PubMed ID: 31830487
    [Abstract] [Full Text] [Related]

  • 11. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.
    Fukumoto K, Fogaça MV, Liu RJ, Duman C, Kato T, Li XY, Duman RS.
    Proc Natl Acad Sci U S A; 2019 Jan 02; 116(1):297-302. PubMed ID: 30559184
    [Abstract] [Full Text] [Related]

  • 12. Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway.
    Deyama S, Ishikawa Y, Yoshikawa K, Shimoda K, Ide S, Satoh M, Minami M.
    Int J Neuropsychopharmacol; 2017 Jul 01; 20(7):575-584. PubMed ID: 28419244
    [Abstract] [Full Text] [Related]

  • 13. Antidepressant-like effects of tomatidine and tomatine, steroidal alkaloids from unripe tomatoes, via activation of mTORC1 in the medial prefrontal cortex in lipopolysaccharide-induced depression model mice.
    Deyama S, Sugie R, Tabata M, Kaneda K.
    Nutr Neurosci; 2024 Aug 01; 27(8):795-808. PubMed ID: 37704369
    [Abstract] [Full Text] [Related]

  • 14. Resolvin E1 Attenuates Chronic Pain-Induced Depression-Like Behavior in Mice: Possible Involvement of Chemerin Receptor ChemR23.
    Suzuki H, Otsuka T, Hitora-Imamura N, Ishimura K, Fukuda H, Fujiwara K, Shuto S, Deyama S, Minami M.
    Biol Pharm Bull; 2021 Aug 01; 44(10):1548-1550. PubMed ID: 34602564
    [Abstract] [Full Text] [Related]

  • 15. Resolvin E3 attenuates lipopolysaccharide-induced depression-like behavior in mice.
    Deyama S, Shimoda K, Ikeda H, Fukuda H, Shuto S, Minami M.
    J Pharmacol Sci; 2018 Sep 01; 138(1):86-88. PubMed ID: 30293959
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor.
    Deyama S, Bang E, Kato T, Li XY, Duman RS.
    Biol Psychiatry; 2019 Jul 15; 86(2):143-152. PubMed ID: 30712809
    [Abstract] [Full Text] [Related]

  • 19. Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
    Deyama S, Kaneda K.
    Neuropharmacology; 2023 Feb 15; 224():109335. PubMed ID: 36403852
    [Abstract] [Full Text] [Related]

  • 20. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
    Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, Ren Q, Zhang JC, Ma M, Toki H, Yamaguchi JI, Chaki S, Shirayama Y, Nakazawa K, Manabe T, Hashimoto K.
    Biol Psychiatry; 2018 Oct 15; 84(8):591-600. PubMed ID: 29945718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.